Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese Society of Palliative Medicine
H Mawatari, T Shinjo, T Morita, H Kohara… - Journal of Palliative …, 2022 - liebertpub.com
H Mawatari, T Shinjo, T Morita, H Kohara, K Yomiya
Journal of Palliative Medicine, 2022•liebertpub.comBackground: Pain is one of the most common symptoms in cancer patients. The Japanese
Society for Palliative Medicine (JSPM) first published its clinical guidelines for the
management of cancer pain in 2010. Since then, more research on cancer pain
management has been reported, and new drugs have become available in Japan. Thus, the
JSPM has now revised the clinical guidelines using a validated methodology. Methods: This
guideline was developed through a systematic review, discussion, and the Delphi method …
Society for Palliative Medicine (JSPM) first published its clinical guidelines for the
management of cancer pain in 2010. Since then, more research on cancer pain
management has been reported, and new drugs have become available in Japan. Thus, the
JSPM has now revised the clinical guidelines using a validated methodology. Methods: This
guideline was developed through a systematic review, discussion, and the Delphi method …
Background: Pain is one of the most common symptoms in cancer patients. The Japanese Society for Palliative Medicine (JSPM) first published its clinical guidelines for the management of cancer pain in 2010. Since then, more research on cancer pain management has been reported, and new drugs have become available in Japan. Thus, the JSPM has now revised the clinical guidelines using a validated methodology.
Methods: This guideline was developed through a systematic review, discussion, and the Delphi method, following a formal guideline development process.
Results: Thirty-five recommendations were created: 19 for the pharmacological management of cancer pain, 6 for the management of opioid-induced adverse effects, and 10 for pharmacological treatment procedures. Due to the lack of evidence that directly addressed our clinical questions, most of the recommendations had to be based on consensus among committee members and other guidelines.
Discussion: It is critical to continue to build high-quality evidence in cancer pain management, and revise these guidelines accordingly.
Mary Ann Liebert